DE69939275D1 - Peptide, bestehend aus zwei funktionellen PTH-Domänen, die durch ein Linkermolekül verknüpft sind, und Derivate davon - Google Patents

Peptide, bestehend aus zwei funktionellen PTH-Domänen, die durch ein Linkermolekül verknüpft sind, und Derivate davon

Info

Publication number
DE69939275D1
DE69939275D1 DE69939275T DE69939275T DE69939275D1 DE 69939275 D1 DE69939275 D1 DE 69939275D1 DE 69939275 T DE69939275 T DE 69939275T DE 69939275 T DE69939275 T DE 69939275T DE 69939275 D1 DE69939275 D1 DE 69939275D1
Authority
DE
Germany
Prior art keywords
pth
derivatives
functional
linker molecule
peptides consisting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69939275T
Other languages
German (de)
English (en)
Inventor
Thomas J Gardella
Henry M Kronenberg
John T Potts Jr
Harald Jueppner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of DE69939275D1 publication Critical patent/DE69939275D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69939275T 1998-12-31 1999-12-30 Peptide, bestehend aus zwei funktionellen PTH-Domänen, die durch ein Linkermolekül verknüpft sind, und Derivate davon Expired - Fee Related DE69939275D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11457798P 1998-12-31 1998-12-31
PCT/US1999/031108 WO2000039278A2 (en) 1998-12-31 1999-12-30 Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules

Publications (1)

Publication Number Publication Date
DE69939275D1 true DE69939275D1 (de) 2008-09-18

Family

ID=22356116

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69939275T Expired - Fee Related DE69939275D1 (de) 1998-12-31 1999-12-30 Peptide, bestehend aus zwei funktionellen PTH-Domänen, die durch ein Linkermolekül verknüpft sind, und Derivate davon

Country Status (7)

Country Link
US (1) US20080058505A1 (enExample)
EP (1) EP1147133B1 (enExample)
JP (1) JP2002533115A (enExample)
AT (1) ATE403678T1 (enExample)
AU (1) AU2486800A (enExample)
DE (1) DE69939275D1 (enExample)
WO (1) WO2000039278A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1133560B1 (en) 1998-11-25 2010-02-17 The General Hospital Corporation Human parathyroid hormone modifications, preparation and use
ATE308609T1 (de) 1998-12-31 2005-11-15 Gen Hospital Corp Pth rezeptor und testverfahren unter verwendung desselben
JP4703091B2 (ja) * 2000-07-10 2011-06-15 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ，センターズ フォー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅに対して免疫原性である複数抗原性ペプチド
CA2454275C (en) 2001-07-23 2012-10-23 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
ATE401345T1 (de) * 2002-08-06 2008-08-15 Aplagen Gmbh Synthetische mimetika von physiologischen bindungsmolekülen
US8088734B2 (en) * 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
MX353986B (es) 2007-08-01 2017-11-06 Massachusetts Gen Hospital Metodos de analisis y seleccion usando receptores acoplados a proteina g y composiciones relacionadas.
CN102448482A (zh) 2009-03-27 2012-05-09 范安德尔研究所 甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法
CN103002906B (zh) 2010-05-13 2017-12-29 总医院有限公司 甲状旁腺激素类似物及其应用
EP2714069A4 (en) * 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc LONG-TERM CONJUGATES WITH TWO HORMONES
US20200354428A9 (en) * 2013-06-23 2020-11-12 Wisconsin Alumni Research Foundation Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US5527772A (en) * 1987-10-20 1996-06-18 Holick; Michael F. Regulation of cell proliferation and differentiation using peptides
US5434246A (en) * 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
AU672790B2 (en) * 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
US5556940A (en) * 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
AU1447600A (en) * 1998-10-22 2000-05-08 Thomas J. Gardella Bioactive peptides and peptide derivatives of parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp)
EP1133560B1 (en) * 1998-11-25 2010-02-17 The General Hospital Corporation Human parathyroid hormone modifications, preparation and use
WO2000031137A1 (en) * 1998-11-25 2000-06-02 The General Hospital Corporation Amino-terminal modified parathyroid hormone (pth) analogs
WO2000032771A1 (en) * 1998-11-30 2000-06-08 The General Hospital Corporation Pth1r and pth3r receptors, methods and uses thereof

Also Published As

Publication number Publication date
WO2000039278A2 (en) 2000-07-06
EP1147133B1 (en) 2008-08-06
AU2486800A (en) 2000-07-31
EP1147133A4 (en) 2003-02-12
WO2000039278A8 (en) 2001-01-11
EP1147133A2 (en) 2001-10-24
JP2002533115A (ja) 2002-10-08
ATE403678T1 (de) 2008-08-15
US20080058505A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
ATE403678T1 (de) Peptide, bestehend aus zwei funktionellen pth- domänen, die durch ein linkermolekül verknüpft sind, und derivate davon
BRPI0407071B8 (pt) peptídeo purificado, seu método de produção e composição farmacêutica para o tratamento de distúrbios gastrointestinais
DK1144607T3 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
CA2395699A1 (en) NUCLEIC ACIDS, PROTEINS AND ANTIBODIES
WO2002057303A3 (en) Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
DE60230046D1 (de) Peptide, die atherosklerotische schädigungen binden
JP2016531546A5 (enExample)
WO2002024222A3 (en) Ligands for g protein coupled receptors and methods of using them
ATE360643T1 (de) Humanes cyr61
PE20010516A1 (es) Peptidos ciclicos con afinidad mejorada por los receptores de somatostatina
DE602005019495D1 (de) Ligand für den Formylpeptidrezeptorähnlichen- 2 (FPRL2) G Protein gekoppelten Rezeptor und dessen Anwendung
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
Stathopoulos et al. Side reactions in the SPPS of Cys-containing peptides
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
Volz et al. Molecular characterization of metal-binding polypeptide domains by electrospray ionization mass spectrometry and metal chelate affinity chromatography
Hara et al. Trifluoroethanol‐containing RP‐HPLC mobile phases for the separation of transmembrane peptides human glycophorin‐A, integrin alpha‐1, and p24: analysis and prevention of potential side reactions due to formic acid
PL377506A1 (pl) Przeciwciało (11C7) anty Nogo oraz jego zastosowanie farmaceutyczne
WO2002026930A3 (en) Nucleic acids, proteins, and antibodies
Bunschoten et al. A general sequence independent solid phase method for the site specific synthesis of multiple sulfated-tyrosine containing peptides
Mokotoff et al. Caution in the use of 2‐iminothiolane (Traut's reagent) as a cross‐linking agent for peptides. The formation of N‐peptidyl‐2‐iminothiolanes with bombesin (BN) antagonist (d‐Trp6, Leu13‐ψ [CH2NH]‐Phe14) BN6− 14 and d‐Trp‐Gln‐Trp‐NH2
Pillai et al. A flexible method for preparation of peptide homo‐and heterodimers functionalized with affinity probes, chelating ligands, and latent conjugating groups
Decalf et al. A novel method to produce synthetic murine CXCL10 for efficient screening of functional variants
Koglin et al. Novel modified and radiolabelled neuropeptide Y analogues to study Y-receptor subtypes
ATE368750T1 (de) Screening-verfahren zum identifizieren von g- proteinen und anderen verbindungen,die die phosphodiesterase (pde)-aktivität beeinflussen
van Strijp et al. Anton Bunschoten, za John AW Kruijtzer, za Johannes H. Ippel, Carla JC de Haas, b

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee